Strategic Initiative
Slingshot members are tracking this corporate initiative:
Mannkind makes EpiPen alternative their lead program
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MNKD |
|
|
||||
Additional Information
“We view that as our lead program at this point,” MannKind CEO and CFO Matthew Pfeffer said. “Not because of what’s going on in the news today, but because it just makes sense. It’s been in development for some time.”
“We have every reason to believe it can be much cheaper (than an EpiPen),” he said. “It will be price competitive, otherwise we wouldn’t have done it.”
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Aug 29, 2016 Projected Implementation: Q3, 2016 Relevance Tracked Until: Q2, 2017
Related Projects
-
Don’t see a project related to the strategic initiative you care about?
Related Keywords
Epipen, Epinephrine
